ADAMTS13 and thrombotic thrombocytopenic purpura: The diagnosis of acquired TTP with severely reduced ADAMTS-13 activity and elevated level of anti-ADAMTS-13 antibodies suggests a more intensive requirement for plasma therapy, increased mortality, and the risk of refractory disease which might need further immunosuppressive therapy.73